WO2004080462A1 - c-Kitキナーゼ阻害剤 - Google Patents
c-Kitキナーゼ阻害剤 Download PDFInfo
- Publication number
- WO2004080462A1 WO2004080462A1 PCT/JP2004/003087 JP2004003087W WO2004080462A1 WO 2004080462 A1 WO2004080462 A1 WO 2004080462A1 JP 2004003087 W JP2004003087 W JP 2004003087W WO 2004080462 A1 WO2004080462 A1 WO 2004080462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- kit kinase
- cancer
- kit
- methoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Definitions
- the present invention relates to a c-Kit kinase inhibitor, and a therapeutic agent for a disease caused by excessive activation of c-Kit kinase containing a c_Kit kinase inhibitor as an active ingredient.
- Intracellular signaling by receptor tyrosine kinases contributes to cell proliferation, differentiation and metabolism, and as a result, causes various diseases including cancer (Kolibaba KS et al. A. 1333, F217-F248, 1997; Sheijen I. et al., Oncogene 21, 3314-3333, 2002).
- C-Kit kinase binds to its specific ligand, SCF (Stem cell factor), to form its own. It is known that kinase activity is activated following dimerization, resulting in phosphorylation of various c-Kit kinase substrates present in cells (Blume-Jensen P. et al., EMB0 J. 10, 4121-4128, 1991; Lev S. et al., EMB0 J., 10, 647-654, 1991).
- C-Kit kinase The abnormal activation of C-Kit kinase is thought to be a proliferative signal in certain types of cancer cells (examples are described below) and cause cancer or malignancy. You.
- Acute myelogenous leukemia Acute myelogenous leukemia (AMD): Many (60-80%) patients with acute myelogenous leukemia show c-Kit kinase expression and are derived from those patients. Blast proliferation was stimulated by SCF stimulation In addition, in 1V18 patients, activation of C-Kit kinase was seen without SCF stimulation, and these patients had activating mutations in c_Kit kinase (Lev S. et al., EMB0 J., 10, 647-654, 1991; Wang C. et al. Leukemia 3, 699-702, 1989; Kanakura Y. et al. Leuk. Lymph. 10, 35-41, 1993; Ikeda H. et al. Blood, 78, 2962-2968, 1991; Ikeda H. et al. Exp. Hematol. 21, 1686-1694, 1993).
- mast cell leukemia It has been reported that mast cell leukemia has a c_Kit kinase activation mutation in a mast cell leukemia cell line that develops in patients with mastocytosis (Furitsu T. et al., J. Clin. Invest., 92, 1736-1744, 1993).
- SCLC Small cell lung carcinoma
- GIST gastrointestinal stromal tumors
- Kit kinase It is defined as stromal carcinoma arising in the gastrointestinal tract expressing Kit kinase. Activating mutations are found in about half of GISTs, and — J mutations are more frequent in highly aggressive GISTs, suggesting a potential prognostic factor (Lasota J. et al. , Am. J. Pathol., 157, 109d 1095, 2000; Taniguchi M. et al., Cancer Res., 59, 4297-4300, 1999).
- Testicular cancer Testicular cancer: Carcinoma in situ (CIS), which is considered to be a precancerous lesion, progresses to tumors called seminoma and non-seminoma. High expression of C-Kit kinase has been reported in CIS and seminoma (Strohmeyer T. et al., Cancer Res., 51, 1811-1816, 1991). Furthermore, in recent years, the expression of activating mutations in c-Kit kinase in seminoma has been reported (Tian Q., et al. Am. J. Pathol., 154, 1643-1647, 1999).
- Ovarian cancer In normal ovarian epithelium, only SCF is expressed and c-Kit kinase is not expressed, but in benign ovarian cancer in the early stage of canceration, It has been reported that both c-Kit kinase and SCF are expressed, and conversely, the expression of C-Kit kinase decreases in malignant ovarian cancer. 'These results suggest that c-Kit kinase plays an important role in the development of ovarian cancer
- Brain cancer Expression of c-Kit kinase was observed in the most aggressive glioblastoma cell line and tissue among brain tumors. It has been reported that glioblastoma cell lines expressing Kit kinases were stimulated to proliferate by SCF stimulation (Berdel WE et al., Cancer Res., 52, 3498-3502, 1992).
- Neuroblastoma Both SCF and C-Kit kinase are expressed in neuroblastoma cell lines and tissue specimens, which are famous as cancers occurring in children. In many cases, it has been reported that anti-C-Kit kinase antibody suppresses the growth of neuroblastoma cell lines, and that autocrine promotes the growth (Cohen PS, Blood, 84, 3465). -3472, 1994).
- Colorectal cancer c-Kit kinase and its ligand, SCF, were co-expressed in colorectal cancer tissues, whereas both were expressed in normal mucosal tissues. I could't. In addition, colorectal cancer cell lines are increased by SCF stimulation. Breeding was promoted. (Bellone G., et al. J. Cell. Physiol., 172, 1-11, 1997).
- c-Kit kinase excessive activation of c-Kit kinase is thought to be responsible for immune abnormalities such as mastocytosis, asthma, and chronic rhinitis caused by excess mast cells.
- Mastocytosis is a general term for various conditions characterized by mast cell hyperproliferation. (Metcalfe, J. Invest.
- Activation of c-Kit kinase in response to SCF stimulation is not only essential for mast cell differentiation, survival, and proliferation, It promotes the induction of various factors from mast cells, and it has been reported that these factors play important roles in eosinophil differentiation, viability and invasiveness (Okayaraa et al., Int. Arch. Aller. Immunol., 114, 75-77, 1997; Okayama et al., Eur. J. Immunol., 28, 708-715, 1998; Metcalf et al., Proc. Natl. Acad. Sci., 95, 6408-6421, 1998; Kay et al., Int. Arch. Aller. Immunol., 113, 196—
- C-Kit kinase is thought to be closely related to the development and malignancy of some cancers and diseases considered to be caused by excess mast cells. Inhibitors were considered useful as therapeutics for these diseases.
- An object of the present invention is to find a new compound showing C-Kit kinase inhibitory activity and to develop a therapeutic agent for a disease caused by c-Kit kinase.
- a compound having a C-Kit kinase inhibitory action a compound having an indrin skeleton has been reported so far (W01 / 45689).
- a compound having a quinazoline skeleton has an inhibitory effect on c-Kit kinase (W001 / 47890), and a related compound (KRN633) also has an inhibitory effect on c-Kit kinase.
- VEGF vascular endothelial growth factor receptor
- FGF2 FGF2
- HGF stimulation W0 02/32872
- the compound represented by the following general formula I is VEGF It has been found to have a strong inhibitory effect on c_Kit kinase as well as kinase, and it has been found that it has an activity of suppressing proliferation of cancer cells expressing c-Kit kinase.
- the present invention relates to the following.
- R 1 is a methyl group, a 2-methoxyl group or a compound of formula II
- R a 3 denotes a methyl group, cyclopropylmethyl group or Shianomechiru group;
- R a 1 is a hydrogen atom, a fluorine atom or a hydroxyl group;
- R 32 is
- 1 means a pyrrolidyl group, 1 a pyridinyl group, 4 1 a morphofuryl group, a dimethylamino group or a getylamino group.
- R 2 is in Shiano radical or formula one CONHR a4 (wherein, R a4 represents a hydrogen atom, C - means 8 Shikuroaruko alkoxy group - 6 alkyl le group, C 3 - 8 cycloalkyl group, CI- 6 alkoxy or C 3 Means a group represented by:
- R 3 is a hydrogen atom, a methyl group, a trifluoromethyl group, a chlorine atom or a fluorine atom Means;
- R 4 represents a hydrogen atom, a methyl group, an ethyl group, an n-propyl group, a cyclopropyl group, a 2-thiazolyl group or a 4-fluorophenyl group.
- a C-Kit kinase inhibitor comprising a compound represented by the formula (I) or a salt thereof or a hydrate thereof as an active ingredient. 2. The C-Kit kinase inhibitor according to 1, wherein R 1 is a methyl group.
- R 2 is a group represented by the formula: CONHR a4 (wherein, R a4 represents a hydrogen atom or a methoxy group.) .
- N6-Methoxy-4-1 (3-chloro-4-1 (((cyclopropylamino) carbonyl) amino) phenoxy) -1 7-Methoxy-6-quinolinecarboxamide
- Cancers that overexpress c-Kit kinase or express mutant c-Kit kinase include acute myeloid leukemia, mast cell leukemia, small cell lung cancer, GIST, testicular tumor, ovarian cancer, Breast cancer, brain tumor, neuroblastoma or colorectal cancer 7.
- Cancer that overexpresses C-Kit kinase or expresses mutant C-Kit kinase is acute myeloid leukemia, small cell 8.
- a therapeutic agent for mastocytosis, allergic disease or asthma comprising the C-kit kinase inhibitor according to any one of 1 to 1 to 6 as an active ingredient.
- Cancers that overexpress C-Kit kinase or express mutant c-Kit kinase include acute myeloid leukemia, J-cellular leukemia, small cell lung cancer, GIST, testicular tumor, ovarian cancer, The use according to 12, wherein the cancer is breast cancer, brain tumor, neuroblast II to J or colorectal cancer. 14. The use according to 12, wherein the cancer overexpressing c-Kit kinase or expressing mutant c-Kit kinase is acute myeloid leukemia, small cell lung cancer or GIST. 15. Use of the c-Kit kinase inhibitor according to any one of 1 to 6 for the manufacture of a therapeutic agent for mastocytosis, allergy or asthma.
- a compound showing strong c-Kit kinase inhibitory activity was found, and a therapeutic agent for suppressing canceration or malignant transformation of certain cancers, which is considered to be caused by activation of c-Kit kinase. It has become possible to treat mastocytosis allergies, asthma, and other diseases that may be caused by c-Kit.
- FIG. 1 is a diagram showing the results of imunobout of phosphorylated C-Kit kinase by SCF stimulation.
- FIG. 2 is a graph showing the relationship between the number of days after transplantation and the main volume when H562 was transplanted into nude mice.
- Fig. 3 is a diagram showing the results of imnoplot of phosphorylated c-Kit kinase, C-Kit kinase and
- the structural formula of a compound may represent a certain isomer for convenience, but in the present invention, all of the geometric isomers and asymmetric carbons which occur in the structure of the compound are referred to. It includes all isomers such as optical isomers, stereoisomers, tautomers and the like, and mixtures of isomers, and is not limited to the description of formulas for convenience.
- the present invention also encompasses compounds that undergo the metabolism such as oxidation, reduction, hydrolysis, and conjugation in the living body and still exhibit a desired activity. And the compounds which produce the compound of the present invention upon metabolism of the present invention. Furthermore, solvates such as water are also included in the present invention.
- alkyl group "represents a linear or branched alkyl group having 1 to 6 carbon atoms, specifically, for example, methyl, Echiru radical, n —Propyl group, i-propyl group, n-butyl group, i-butyl group, sec— ptinole group, t-butynole group, n-pentynole group, i-pentynole group, sec-pentynole group, t-pentyl group, neopentyl group , 1-methylbutyl group, 2-methylbutyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, n-hexyl group, i-hexyl group, 1-methylpentyl group, 2-methylpentyl group , 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl,
- i-pentinole group sec-pentynole group, t-pentynole group, neopentynole group, 1-methynole ptynole group, 2-methylethynyl group, 1,1 dimethynolepropyne group, 1,2 —Dimethylpropyl group, n-hexyl group, i-hexyl group, more preferably, methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, i-butyl group, sec—Putinole group , T-butyl group, n-pentynole group, i-pentynole group, sec-pentyl group, t-pentyl group, neopentyl group, 1-methylbutyl group, 2-methylbutyl group, 1,1-dimethylpropyl group, 1,2 —
- C 3 one 8 cycloalkyl group means a cyclic alkyl group having 3 to 8 carbon atoms, the two.
- cyclopropyl consequent Examples include a robutyl group, a cyclopentyl group, and a cyclohexyl group.
- it is a cyclopropyl group.
- a "0 ⁇ 6 alkoxy group” means a substituent before Symbol " ⁇ Bok 6 alkyl group” is bonded to an oxygen atom, specifically, for example main butoxy Group, ethoxy group, n-propoxy group, i-propoxy group, n-butoxy group, i-butoxy group, sec-butoxy group, t-butoxy group, n-pentynoleoxy group, i-pentynoleoxy group, sec-pentyloxy group, t-pentyloxy group, neopentynoleoxy group, 1-methinoleptoxy group, 2-methinolebutoxy group, 1,1-dimethylpropoxy group, 1,2-dimethylpropoxy group, n-hexyloxy group, i 1-hexyloxy, 1-methylpentyloxy, 2-methylpentyloxy, 3-methylpentyloxy, 1,1-dimethylbutoxy, 1,2-di
- the "C 3 one 8 cycloalkoxy group” in the present specification means a cyclic alkoxy group having a carbon number of 3-8, specifically, for example, cyclopropoxy group, cyclobutoxy group And a cyclopentyloxy group and a cyclohexyloxy group. Preferably it is a cyclopropoxy group.
- the compound represented by the general formula I according to the present invention is described in WO 02/32872. It can be manufactured by the method described above.
- the "pharmacologically acceptable salt” is not particularly limited, and examples thereof include hydrochloride, sulfate, carbonate, bicarbonate, hydrobromide, and the like.
- Addition salts of inorganic acids such as hydroiodide; addition salts of organic carboxylic acids such as acetate, maleate, lactate, tartrate, trifluoroacetate; methanesulfonate, hydroxymethanesulfonate
- Addition salts of organic sulfonic acids such as hydroxyethanesulfonic acid salt, benzenesulfonic acid salt, toluenesulfonic acid salt, taurine salt; trimethylamine salt, triethylamine salt, pyridine salt, proforcein salt, picoline salt, dicyclone Hexylamine salt, N, N, dibenzylethylenediamine salt, N-methyldalcamine salt, diethanolamine salt, triethanolamine salt Tris (hydroxymethylamino) methan
- the dosage of a pharmaceutical according to the present TsutomuAkira the degree of symptoms, age, sex, weight, dosing forms may vary depending on the type of disease, a normal adult per day 100 / z g ⁇ 10 g Yes, divided into 1 to several doses
- the administration form of the medicament according to the present invention is not particularly limited, and can be orally or parenterally administered by a commonly used method.
- These components include, for example, animal and vegetable oils (soy oil, tallow, synthetic glyceride, etc.), hydrocarbons (liquid paraffin, squalane, solid paraffin, etc.), ester oils (otatildodecyl myristate, Isopropyl myristate ), Higher alcohols (such as cetostearyl alcohol and behenyl alcohol), silicone resins, silicone oils, and surfactants (polyoxyethylene fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters, poly) Oxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene block copolymer, etc., water-soluble polymers (hydroxyxethyl cellulose, polyacrylic acid, carboxybutyl polymer, polyethylene glycolose, polyvinylinolepyrrolidone, methyl / resenorelose, etc.) ), Anorecol
- inorganic acids such as hydrochloric acid and phosphoric acid
- alkali metal salts of inorganic acids such as sodium phosphate
- inorganic bases such as sodium hydroxide
- organic acids lower fatty acids, citric acid, lactic acid, etc.
- alkali metal salts of organic acids such as sodium taenoate and sodium lactate
- organic bases such as arginine and ethanolamine
- Compound 1 was prepared according to the method described in Example 368 of WO 02/32872.
- Compound 2 was prepared according to the method described in Example 583 of WO 02/32872.
- Compound 3 was prepared according to the method described in Example 417 of WO 02/32872.
- Compound 4 was prepared according to the method described in Example 702 of TO 02/32872.
- H526 was cultured in RPMI 1640 medium (manufactured by Nissui Pharmaceutical Co., Ltd.) containing 10% FCS (purchased from Cell Culture Technologies) in a 5% CO 2 incubator (37 ° C.). After culturing, the H526 cells were washed three times with PBS and 0.1 ° /.
- BSA Sigma Co.
- RPMI 1640 medium (hereinafter, BSA-RPMI1640) containing a 1. 0 x I0 5 cells / ml in The cells were suspended, and 50 ⁇ l of the cell suspension was seeded on a round-bottom 96-well plate and cultured in a 5% CO 2 incubator (37 ° C.). After the culture, BSA-RPMI1640 501 containing 200 ng / ml SCF (manufactured by R & D) and BSA-RPMI1640 1001 containing the diluted test substance were added.
- Example 2 Influence of compound 1 on SCF-stimulated c-Kit kinase phosphorylation The effect of Compound 1 on SCF-stimulated phosphorylation of c-Kit kinase expressing small cell lung cancer cell line H526 cell c-Kit kinase molecule was examined.
- H526 were cultured in in RPMI1640 medium containing 10% FCS 5% C0 2 incubator one (3 7 ° C). After culturing, wash the H526 cells three times with PBS, suspend the cells at 5.0 x 10 5 cells / ml with BSA-RPMI1640, and inoculate 1 ml of this cell suspension into a 24-well plate. and incubated 6 hours at% C0 2 incubator (3 7 ° C).
- cell lysate sample was electrophoresed on a 4-20% gradient polyacrylamide gel (manufactured by Daiichi Pure Chemicals Co., Ltd.).
- the membrane was transferred to a PVDF membrane (Araersham pharmacia biotech) in 3 hours, and the transferred membrane was used as a primary antibody, a phospho-c-kit (Tyr719) antibody (Cell Sign 1-) and a secondary antibody Immunoblot was performed using anti-rabbit IgG and HRP-linked antibody (manufactured by Cell Signaling) as antibodies. After washing the membrane, the color was developed with Super Signal (manufactured by PIERCE).
- H526 is 10 ° /. 5 ° / rpm in RPMI1640 medium containing FCS. C0. incubator The cells were cultured at 37 ° C. After collecting the culture solution, the cells were washed twice with PBS and suspended at 5.0 ⁇ 10 7 cells / ml with PBS. This cell suspension was transplanted at 0.1 ml subcutaneously into the right flank of a 6-week-old female Balb nu / nu mice (purchased from Charles River Co., Ltd.). After the transplantation, the administration of the test substance was started when the tumor volume reached about 150 mm 3 , and oral administration was performed twice a day for 14 days. The test substance was suspended in a 0.5% methylcellulose (manufactured by Wako Pure Chemical Industries, Ltd.) solution to a dosage of 0.1 ml / 10 g body weight. .
- tumor volumes were measured twice weekly with a caliper. Tumor volume was measured using a caliper to measure the major axis and minor axis of the tumor, and calculated as 1/2 X major axis X minor axis X minor axis.
- the experiment was performed with 10 animals in the vehicle control group (solvent administration group) and 5 animals in the test substance administration group.
- a cell lysate sample was prepared by adding 3X SDS sample noreloading buffer, followed by heat treatment of the cell lysate sample at 94 ° C for 10 minutes. -Stored frozen at 20 ° C. [0559] Thereafter, a cell lysate sample equivalent to a protein amount of 30 / g was electrophoresed on a 4-20% gradient polyacrylaraide gel (manufactured by Daiichi Pure Chemicals Co., Ltd.).
- Compound 1 reduced the amount of phosphorylated C-Kit in tumor tissue at the dose of 30, 100 mg / kg, while the amount of C-Kit and i3 actin was decreased. The amount was not changed. Compound 1 showed complete inhibition of phosphorylation at 30,100 rag / kg, whereas STI571, a C-kit kinase inhibitor, showed only partial inhibition at 160 rag / kg.
- the compound represented by the general formula I exhibits strong C-Kit kinase inhibitory activity and suppresses the growth of cancer cells activated by c-Kit kinase in vitro and in vivo. Was found. Therefore, it became clear that the compound represented by the general formula I can be used as an anticancer agent for cancer that has become malignant due to activation of c-Kit kinase.
- a C-Kit kinase inhibitor containing a compound represented by the general formula I as an active ingredient is used as a therapeutic agent for diseases such as Mastocytosis, which is considered to be caused by c-Kit, and asthma. Is also suggested to be effective.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT04719054T ATE508747T1 (de) | 2003-03-10 | 2004-03-10 | C-kit kinase-hemmer |
EP04719054A EP1604665B1 (en) | 2003-03-10 | 2004-03-10 | C-kit kinase inhibitor |
JP2005503539A JPWO2004080462A1 (ja) | 2003-03-10 | 2004-03-10 | c−Kitキナーゼ阻害剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-062823 | 2003-03-10 | ||
JP2003062823 | 2003-03-10 | ||
JP2003302803 | 2003-08-27 | ||
JP2003-302803 | 2003-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004080462A1 true WO2004080462A1 (ja) | 2004-09-23 |
Family
ID=32992931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/003087 WO2004080462A1 (ja) | 2003-03-10 | 2004-03-10 | c-Kitキナーゼ阻害剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7994159B2 (ja) |
EP (1) | EP1604665B1 (ja) |
JP (1) | JPWO2004080462A1 (ja) |
AT (1) | ATE508747T1 (ja) |
WO (1) | WO2004080462A1 (ja) |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044788A1 (ja) * | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
WO2005063713A1 (ja) * | 2003-12-25 | 2005-07-14 | Eisai Co., Ltd. | 4−(3−クロロ−4−(シクロプロピルアミノカルボニル)アミノフェノキシ)−7−メトキシ−6−キノリンカルボキサミドの塩またはその溶媒和物の結晶およびそれらの製造方法 |
WO2006137474A1 (ja) | 2005-06-23 | 2006-12-28 | Eisai R & D Management Co., Ltd. | 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキサミドの塩のアモルファスおよびその製造方法 |
WO2007015569A1 (ja) | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
WO2007052850A1 (ja) * | 2005-11-07 | 2007-05-10 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質とc-kitキナーゼ阻害物質との併用 |
WO2007061127A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
WO2008001956A1 (fr) | 2006-06-29 | 2008-01-03 | Eisai R & D Management Co., Ltd. | Agent thérapeutique contre la fibrose hépatique |
WO2008026748A1 (fr) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
US7550483B2 (en) | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
US7612092B2 (en) | 2000-10-20 | 2009-11-03 | Eisai R & D Management Co., Ltd. | Nitrogen-containing aromatic derivatives |
EP2281901A2 (en) | 2005-08-02 | 2011-02-09 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
WO2011021597A1 (ja) * | 2009-08-19 | 2011-02-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体含有医薬組成物 |
US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
JP4834553B2 (ja) * | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
WO2011162343A1 (ja) | 2010-06-25 | 2011-12-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 |
WO2012144463A1 (ja) * | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
WO2013014170A1 (en) | 2011-07-27 | 2013-01-31 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
WO2014098176A1 (ja) * | 2012-12-21 | 2014-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
US10259791B2 (en) | 2014-08-28 | 2019-04-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US11090386B2 (en) | 2015-02-25 | 2021-08-17 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006257919A1 (en) * | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant kit protein |
WO2008115300A1 (en) * | 2006-12-01 | 2008-09-25 | Apocell, Inc. | C-kit phosphorylation in cancer |
JP5399926B2 (ja) * | 2008-01-29 | 2014-01-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管阻害物質とタキサンとの併用 |
US20190000797A1 (en) | 2015-08-20 | 2019-01-03 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
EP3581183B1 (en) | 2017-02-08 | 2023-11-29 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
WO2018157411A1 (zh) * | 2017-02-28 | 2018-09-07 | 深圳市塔吉瑞生物医药有限公司 | 取代的含氮芳环化合物及其应用 |
WO2019222075A1 (en) | 2018-05-14 | 2019-11-21 | Merck Sharp And Dohme Corp. | Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist |
CN110845408A (zh) * | 2018-08-20 | 2020-02-28 | 润佳(苏州)医药科技有限公司 | 同位素富集的乐伐替尼 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000043366A1 (fr) * | 1999-01-22 | 2000-07-27 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline |
WO2002032872A1 (en) * | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Nitrogenous aromatic ring compounds |
WO2004039782A1 (ja) * | 2002-10-29 | 2004-05-13 | Kirin Beer Kabushiki Kaisha | Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
EP0154434B1 (en) * | 1984-02-17 | 1993-01-27 | Genentech, Inc. | Human transforming growth factor and precursor or fragment thereof, cells, dna, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods |
DE8411409U1 (de) | 1984-04-11 | 1984-08-30 | Dr.-Ing. Walter Frohn-Betriebe, 8000 München | Entgasungsventil fuer lager- und/oder transportbehaelter |
ATE92499T1 (de) * | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
JPS62168137A (ja) * | 1985-12-20 | 1987-07-24 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料およびその処理方法 |
JPH07106295B2 (ja) | 1986-07-22 | 1995-11-15 | エーザイ株式会社 | 調湿剤 |
CA1339136C (en) | 1987-07-01 | 1997-07-29 | Sailesh Amilal Varia | Amorphous form of aztreonam |
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US4983615A (en) | 1989-06-28 | 1991-01-08 | Hoechst-Roussel Pharmaceuticals Inc. | Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders |
US5180818A (en) * | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
GB9105677D0 (en) | 1991-03-19 | 1991-05-01 | Ici Plc | Heterocyclic compounds |
US5367057A (en) * | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
JPH04341454A (ja) | 1991-05-16 | 1992-11-27 | Canon Inc | シート収納装置 |
US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
AU678764B2 (en) * | 1992-06-03 | 1997-06-12 | Case Western Reserve University | Bandage for continuous application of biologicals |
JPH06153952A (ja) | 1992-11-26 | 1994-06-03 | Nobuaki Tamamaki | 微量未知二重鎖dna分子の増幅、標識を行うための前処理方法 |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
JPH07176103A (ja) | 1993-12-20 | 1995-07-14 | Canon Inc | 光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体 |
GB9326136D0 (en) | 1993-12-22 | 1994-02-23 | Erba Carlo Spa | Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents |
US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
JP3660391B2 (ja) | 1994-05-27 | 2005-06-15 | 株式会社東芝 | 半導体装置の製造方法 |
JPH0848078A (ja) | 1994-08-05 | 1996-02-20 | Nippon Paper Ind Co Ltd | 感熱記録体 |
US5656454A (en) * | 1994-10-04 | 1997-08-12 | President And Fellows Of Harvard College | Endothelial cell-specific enhancer |
IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
US5658374A (en) * | 1995-02-28 | 1997-08-19 | Buckman Laboratories International, Inc. | Aqueous lecithin-based release aids and methods of using the same |
US5624937A (en) * | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
JPH0923885A (ja) | 1995-07-12 | 1997-01-28 | Dai Ichi Seiyaku Co Ltd | 遺伝子発現ライブラリー及びその製造法 |
US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
US6143764A (en) * | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
JPH09234074A (ja) | 1996-03-04 | 1997-09-09 | Sumitomo Electric Ind Ltd | アダプター二本鎖dna及びそれを用いたdna増幅方法 |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
US6090556A (en) | 1997-04-07 | 2000-07-18 | Japan Science & Technology Corporation | Method for quantitatively determining the expression of a gene |
WO1999001738A2 (en) * | 1997-06-30 | 1999-01-14 | University Of Maryland, Baltimore | Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis |
JP3765918B2 (ja) | 1997-11-10 | 2006-04-12 | パイオニア株式会社 | 発光ディスプレイ及びその駆動方法 |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
PL205557B1 (pl) * | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
JP2000328080A (ja) | 1999-03-12 | 2000-11-28 | Shin Etsu Chem Co Ltd | シートベルト用低摩擦化処理剤 |
YU13200A (sh) * | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
CN101073668A (zh) * | 1999-04-28 | 2007-11-21 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
WO2001012600A1 (en) * | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
JP2001131071A (ja) | 1999-10-29 | 2001-05-15 | Meiji Seika Kaisha Ltd | 非晶質および非晶質を含有する医薬組成物 |
AU784338B2 (en) | 1999-11-01 | 2006-03-16 | Curagen Corporation | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
MXPA02006263A (es) * | 1999-12-22 | 2004-02-26 | Sugen Inc | Metodos de modulacion de la funcion de la cinasa de tirosina c-kit de la proteina con compuestos de indolinona. |
WO2001047890A1 (fr) * | 1999-12-24 | 2001-07-05 | Kirin Beer Kabushiki Kaisha | Quinoline, derives de la quinazoline et medicaments contenant ces substances |
DE60018216T2 (de) * | 1999-12-24 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Kondensierte purinderivate |
ME00415B (me) * | 2000-02-15 | 2011-10-10 | Pharmacia & Upjohn Co Llc | Pirol supstituisani 2-indol protein kinazni inhibitori |
JP3657203B2 (ja) | 2000-04-21 | 2005-06-08 | エーザイ株式会社 | 銅クロロフィリン塩含有液剤組成物 |
EP2281821B1 (en) * | 2000-05-15 | 2014-10-22 | Takeda Pharmaceutical Company Limited | Process for producing a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole |
JP2004512023A (ja) * | 2000-06-09 | 2004-04-22 | コリクサ コーポレイション | 結腸癌の治療および診断のための組成物および方法 |
TWI283575B (en) * | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
WO2002041882A2 (en) | 2000-11-22 | 2002-05-30 | Novartis Ag | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
AU2002254152A1 (en) * | 2001-03-08 | 2002-09-24 | Millennium Pharmaceuticals | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
JP3602513B2 (ja) | 2001-04-27 | 2004-12-15 | 麒麟麦酒株式会社 | アゾリル基を有するキノリン誘導体およびキナゾリン誘導体 |
TWI324154B (ja) * | 2001-04-27 | 2010-05-01 | Kyowa Hakko Kirin Co Ltd | |
JP2003026576A (ja) | 2001-05-09 | 2003-01-29 | Eisai Co Ltd | 味覚改善製剤 |
AU2002342335B2 (en) | 2001-05-16 | 2006-02-02 | Novartis Ag | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
GB0119467D0 (en) | 2001-08-09 | 2001-10-03 | Smithkline Beecham Plc | Novel compound |
WO2003023360A2 (en) * | 2001-09-10 | 2003-03-20 | Meso Scale Technologies, Llc | Methods and apparatus for conducting multiple measurements on a sample |
DE60228278D1 (de) * | 2001-09-20 | 2008-09-25 | Ab Science | Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung |
WO2003028711A2 (en) | 2001-09-27 | 2003-04-10 | Novartis Ag | Use of c-kit inhibitors for the treatment of myeloma |
EP1435959A2 (en) * | 2001-10-09 | 2004-07-14 | University of Cincinnati | Inhibitors of the egf receptor for the treatment of thyroid cancer |
EP1447405A4 (en) * | 2001-10-17 | 2005-01-12 | Kirin Brewery | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS |
EP1481678A4 (en) * | 2002-03-05 | 2009-12-30 | Eisai R&D Man Co Ltd | ANTITUMORAL AGENT CONTAINING A SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND AND AN ANGIOGENESIS INHIBITOR |
JP2005520834A (ja) | 2002-03-20 | 2005-07-14 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 小細胞肺癌の同定、診断、および治療のための方法および組成物 |
AU2003235838A1 (en) | 2002-05-01 | 2003-11-17 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor |
UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
AU2003251968A1 (en) | 2002-07-16 | 2004-02-02 | Children's Medical Center Corporation | A method for the modulation of angiogenesis |
MXPA05001536A (es) | 2002-08-30 | 2005-04-19 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
BR0315169A (pt) | 2002-10-09 | 2005-08-23 | Kosan Biosciences Inc | Referência cruzada a pedidos de patente relacionados |
GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
JP4749660B2 (ja) | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
US8697094B2 (en) * | 2002-10-16 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
CA2502979A1 (en) | 2002-11-06 | 2004-05-21 | Cyclacel Limited | Pharmaceutical composition comprising a cdk inhibitor and gemcitabine |
GB0226434D0 (en) | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
AR042042A1 (es) | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
ES2387909T3 (es) | 2003-01-14 | 2012-10-03 | Cytokinetics, Inc. | Compuestos, composiciones y procedimientos de tratamiento de la insuficiencia cardiaca |
WO2004078144A2 (en) | 2003-03-05 | 2004-09-16 | Celgene Corporation | Diphenylethylene compounds and uses thereof |
JPWO2004080462A1 (ja) | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | c−Kitキナーゼ阻害剤 |
JPWO2004081047A1 (ja) * | 2003-03-14 | 2006-06-29 | 大正製薬株式会社 | モノクローナル抗体及びこれを産生するハイブリドーマ |
US20070117842A1 (en) * | 2003-04-22 | 2007-05-24 | Itaru Arimoto | Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same |
ATE395052T1 (de) * | 2003-08-15 | 2008-05-15 | Ab Science | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
JP2007505938A (ja) | 2003-09-23 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | Vegf受容体阻害剤と化学療法剤の組み合わせ |
EP2392564B1 (en) | 2003-09-26 | 2013-10-23 | Exelixis, Inc. | c-Met modulators and methods of use |
WO2005044788A1 (ja) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
CA2546673A1 (en) | 2003-11-28 | 2005-06-09 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
AU2004296376B2 (en) | 2003-12-05 | 2010-03-04 | Bristol-Myers Squibb Company | Inhibitors of type 2 vascular endothelial growth factor receptors |
RS54033B1 (en) | 2003-12-25 | 2015-10-30 | Eisai R&D Management Co. Ltd. | CRYSTAL FORM OF THE SALTS 4- (3-CHLORO-4- (CYCLOPROPYLAMINOCARBONYL) AMINO-PHENOXY) -7-METHOXY-6-HINOLINKARBOXAMIDE OR ITS SOLVATES AND THE PROCESS FOR THEIR PRODUCTION |
CA2543859A1 (en) | 2004-02-27 | 2005-09-09 | Eisai Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (1) |
KR20050091462A (ko) | 2004-03-12 | 2005-09-15 | 한국과학기술연구원 | 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제 |
JP4341454B2 (ja) | 2004-04-08 | 2009-10-07 | トヨタ自動車株式会社 | 固体電解質型燃料電池の製造方法 |
KR100986945B1 (ko) * | 2004-06-03 | 2010-10-12 | 에프. 호프만-라 로슈 아게 | 젬시타빈 및 egfr-억제제로의 치료 |
WO2006030947A1 (ja) | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
US8772269B2 (en) * | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
KR20070053205A (ko) * | 2004-09-17 | 2007-05-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 의약 조성물 |
US20060079494A1 (en) * | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
EP1827445A2 (en) | 2004-11-22 | 2007-09-05 | King Pharmaceuticals Research and Development Inc. | Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists |
EP1824843A2 (en) | 2004-12-07 | 2007-08-29 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
AU2006217692A1 (en) | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | Novel combinational use of sulfonamide compound |
JP5106098B2 (ja) | 2005-02-28 | 2012-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド化合物の抗癌剤との新規併用 |
CA2606719C (en) | 2005-06-23 | 2010-08-10 | Eisai R & D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same |
US7550483B2 (en) * | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
JP2009502960A (ja) | 2005-07-27 | 2009-01-29 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ |
US20100105031A1 (en) | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
US20090053236A1 (en) | 2005-11-07 | 2009-02-26 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
US20090247576A1 (en) | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
-
2004
- 2004-03-10 JP JP2005503539A patent/JPWO2004080462A1/ja active Pending
- 2004-03-10 WO PCT/JP2004/003087 patent/WO2004080462A1/ja active Application Filing
- 2004-03-10 US US10/797,903 patent/US7994159B2/en not_active Expired - Fee Related
- 2004-03-10 EP EP04719054A patent/EP1604665B1/en not_active Expired - Lifetime
- 2004-03-10 AT AT04719054T patent/ATE508747T1/de not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000043366A1 (fr) * | 1999-01-22 | 2000-07-27 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline |
WO2002032872A1 (en) * | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Nitrogenous aromatic ring compounds |
WO2004039782A1 (ja) * | 2002-10-29 | 2004-05-13 | Kirin Beer Kabushiki Kaisha | Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
Cited By (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8372981B2 (en) | 2000-10-20 | 2013-02-12 | Eisai R&D Management Co., Ltd. | Nitrogen-containing aromatic derivatives |
US7973160B2 (en) | 2000-10-20 | 2011-07-05 | Eisai R&D Management Co., Ltd. | Nitrogen-containing aromatic derivatives |
US7612092B2 (en) | 2000-10-20 | 2009-11-03 | Eisai R & D Management Co., Ltd. | Nitrogen-containing aromatic derivatives |
US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
WO2005044788A1 (ja) * | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
US8058474B2 (en) | 2003-11-11 | 2011-11-15 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
US7612208B2 (en) | 2003-12-25 | 2009-11-03 | Eisai R&D Management Co., Ltd. | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
WO2005063713A1 (ja) * | 2003-12-25 | 2005-07-14 | Eisai Co., Ltd. | 4−(3−クロロ−4−(シクロプロピルアミノカルボニル)アミノフェノキシ)−7−メトキシ−6−キノリンカルボキサミドの塩またはその溶媒和物の結晶およびそれらの製造方法 |
EP2567955A2 (en) | 2003-12-25 | 2013-03-13 | Eisai R&D Management Co., Ltd. | Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
JP4834553B2 (ja) * | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
US9504746B2 (en) | 2004-09-17 | 2016-11-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
WO2006137474A1 (ja) | 2005-06-23 | 2006-12-28 | Eisai R & D Management Co., Ltd. | 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキサミドの塩のアモルファスおよびその製造方法 |
US7550483B2 (en) | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
AU2006260148B2 (en) * | 2005-06-23 | 2009-07-16 | Eisai R&D Managment Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)- 7-methoxy-6-quinolinecarboxamide and process for producing the same |
AU2006260148B9 (en) * | 2005-06-23 | 2009-09-17 | Eisai R&D Managment Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)- 7-methoxy-6-quinolinecarboxamide and process for producing the same |
EP1894918A1 (en) * | 2005-06-23 | 2008-03-05 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same |
JP4733700B2 (ja) * | 2005-06-23 | 2011-07-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 4−(3−クロロ−4−(シクロプロピルアミノカルボニル)アミノフェノキシ)−7−メトキシ−6−キノリンカルボキサミドの塩のアモルファスおよびその製造方法 |
EP1894918A4 (en) * | 2005-06-23 | 2011-06-22 | Eisai R&D Man Co Ltd | AMORPHIC SALT OF 4- (3-CHLORO-4- (CYCLOPROPYLAMINOCARBONYL) AMINOPHENOXY) -7-METHOXY-6-CHINOLINE CARBOXAMIDE AND METHOD OF PREPARATION THEREOF |
JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
WO2007015569A1 (ja) | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
EP2281901A2 (en) | 2005-08-02 | 2011-02-09 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
US8969344B2 (en) | 2005-08-02 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
WO2007052850A1 (ja) * | 2005-11-07 | 2007-05-10 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質とc-kitキナーゼ阻害物質との併用 |
AU2006309551B2 (en) * | 2005-11-07 | 2012-04-19 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
JPWO2007052849A1 (ja) * | 2005-11-07 | 2009-04-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質とc−kitキナーゼ阻害物質との併用 |
WO2007052849A1 (ja) * | 2005-11-07 | 2007-05-10 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質とc-kitキナーゼ阻害物質との併用 |
WO2007061127A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
WO2007061130A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
WO2008001956A1 (fr) | 2006-06-29 | 2008-01-03 | Eisai R & D Management Co., Ltd. | Agent thérapeutique contre la fibrose hépatique |
WO2008026748A1 (fr) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
JP5319306B2 (ja) * | 2007-01-29 | 2013-10-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌治療用組成物 |
US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
WO2011021597A1 (ja) * | 2009-08-19 | 2011-02-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体含有医薬組成物 |
CN102470133B (zh) * | 2009-08-19 | 2013-08-28 | 卫材R&D管理有限公司 | 含有喹啉衍生物的药物组合物 |
KR101496395B1 (ko) | 2009-08-19 | 2015-02-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체 함유 의약 조성물 |
JP5048871B2 (ja) * | 2009-08-19 | 2012-10-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体含有医薬組成物 |
CN102470133A (zh) * | 2009-08-19 | 2012-05-23 | 卫材R&D管理有限公司 | 含有喹啉衍生物的药物组合物 |
KR20130088047A (ko) | 2010-06-25 | 2013-08-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제 |
WO2011162343A1 (ja) | 2010-06-25 | 2011-12-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
WO2012144463A1 (ja) * | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
US11598776B2 (en) | 2011-06-03 | 2023-03-07 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
US9168245B2 (en) | 2011-07-27 | 2015-10-27 | Ab Science | Selective protein kinase inhibitors |
WO2013014170A1 (en) | 2011-07-27 | 2013-01-31 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
JPWO2014098176A1 (ja) * | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
CN104755463A (zh) * | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | 非晶态形式的喹啉衍生物及其生产方法 |
WO2014098176A1 (ja) * | 2012-12-21 | 2014-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
US10259791B2 (en) | 2014-08-28 | 2019-04-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
US10407393B2 (en) | 2014-08-28 | 2019-09-10 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
US10822307B2 (en) | 2014-08-28 | 2020-11-03 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
US11186547B2 (en) | 2014-08-28 | 2021-11-30 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
US11090386B2 (en) | 2015-02-25 | 2021-08-17 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
Also Published As
Publication number | Publication date |
---|---|
US20040253205A1 (en) | 2004-12-16 |
ATE508747T1 (de) | 2011-05-15 |
EP1604665A4 (en) | 2009-05-13 |
EP1604665B1 (en) | 2011-05-11 |
JPWO2004080462A1 (ja) | 2006-06-08 |
EP1604665A1 (en) | 2005-12-14 |
US7994159B2 (en) | 2011-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004080462A1 (ja) | c-Kitキナーゼ阻害剤 | |
Xu et al. | Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells | |
Sun et al. | Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain | |
WO2018215795A2 (en) | Senolytic compounds | |
JP2020158507A6 (ja) | 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療 | |
KR101877840B1 (ko) | 암 치료용 화합물을 확인하는 방법 | |
Lee et al. | Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells | |
EP1401429A2 (en) | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis | |
KR20200098536A (ko) | Dux4 발현과 관련된 질병의 치료를 위한 화합물 | |
WO2012080497A2 (en) | Methods of treatment and prevention of eye diseases | |
CN103893181A (zh) | 化合物在制备治疗转移瘤的药物中的应用 | |
TW201217361A (en) | Method of treating abnormal cell growth | |
JP2014111653A (ja) | 小児腫瘍の治療 | |
JP2013504550A (ja) | 癌細胞アポトーシス | |
AU2014241816B9 (en) | Novel therapy for prostate carcinoma | |
KR101957613B1 (ko) | 아릴 아민 치환된 퀸옥살린의 항암 약물로서 용도 | |
TWI434680B (zh) | 二萜類化合物於治療攝護腺癌之用途 | |
CA2612333C (en) | Inhibition of osteolytic lesions by src kinase inhibitors | |
US11110098B2 (en) | Methods and medicaments for the treatment of renal cell carcinoma | |
ES2363339T3 (es) | Inhibidor de c-kit cinasa. | |
KR20170085993A (ko) | Alk 저해제에 대한 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 스타틴계 약물의 용도 | |
JP6936496B2 (ja) | 移植片対宿主病の治療剤又は予防剤、ファイブロサイト浸潤抑制剤、及び涙液減少と杯細胞の減少の抑制剤 | |
US9101630B2 (en) | Use of PDGF-R inhibitors for the treatment of lymph node metastasis of gastric cancer | |
WO2023008511A1 (ja) | Bap1およびpbrm1の少なくとも1つの機能低下を有する腫瘍に対する医薬組成物および抗腫瘍剤 | |
JP2023524151A (ja) | 抗癌剤タンパク質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005503539 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004719054 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004719054 Country of ref document: EP |